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osting by EAbstract Polymorphonuclear neutrophils (PMN) have contributed only to the innate immune
response, due to their phagocytosis activity. They have a short life time. Some studies of PMN cyto-
kine production and expression of numerous cell surface proteins have suggested that PMN are
likely to inﬂuence adaptive responses and may satisfy the criteria of antigen presenting cells. Flow
cytometry was used in the present study for the detection of cell surface major histocompatibility
complex (MHC) class II, CD80 and CD86 required for antigen presentation and subsequent T-cell
activation. Human peripheral blood neutrophils were used for this purpose. In vitro stimulation of
PMN with IL-2 or IL-4 for 24 h showed expression of MHC class II, CD80 and CD86. These obser-
vations, therefore, provide support to the hypothesis that human PMN have the potential to express
molecules required for antigen presentation.
 2010 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.ar neutrophil; MHC, major
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lsevier1. Introduction
Polymorphonuclear neutrophils (PMN) possess a very short
half-life in the circulation because they constitutively undergo
apoptosis [1,2]. Under certain conditions PMN play an impor-
tant role in the effectors arm of host immune defense through
the clearance of immune complexes, phagocytosis of opsonized
particles, and release of inﬂammatory mediators [3–5]. During
the last few years the image of PMN has changed considerably.
Traditionally considered to be the ﬁrst line defense against
bacterial infection it became increasingly clear that PMN also
participate in chronic inﬂammation disease and regulation of
the immune response when appropriately activated [6]. For
surface molecules, there are several reports that PMN from a
variety of species can express major histocompatibility com-
plex (MHC) class II and costimulatory molecules (CD80 and
116 Bahaa Kenawy Abuel-Hussien Abdel-SalamCD86) [6–10]. Under certain stimulation murine neutrophils
could present Class II restricted antigen [11].
PMN function and recruitment to the site of inﬂammation
have been shown to be upregulated by various cytokines,
including interleukin (IL)-1, IL-8, tumor necrosis factor
(TNF), interferon-c (IFN-c), and granulocyte macrophage-
colony stimulating factor (GM-CSF) [5,12]. In addition IL-
15 stimulated PMN acquire HLA-DR [13].
Classically, IL-2 has been considered to be a lymphocyte-
activating and growth-promoting factor, and has been widely
studied on T cells and NK cells [14]. Monocytes have been re-
ported to express IL-2Rb and to be activated by IL-2 for
tumoricidal activity [15]. Thus far, PMN have not been studied
for their interaction with IL-2, and their possession of IL-2R is
unknown. The direct effect of IL-2 on PMN, especially the
mechanisms involved in the activation of PMN, is unknown,
although the ability of other immune cells to respond to IL-2
is well studied. Preliminary studies have shown that PMN have
the capacity to respond to IL-2 with increased antifungal activ-
ity [16]. More importantly, it has been identiﬁed that PMN
express surface receptors for IL-2, but only IL-2Rb and not
IL-2Ra is present [16].
IL-4 production has been found to occur in thymocytes,
mature T-cells, certain malignant T-cells, mast-cells and baso-
philes and occasionally, in transformed B-cells [17]. In addi-Figure 1 Cytoﬂourometry of the MHC class II induction in the wh
PMN (24 h). (C) Stimulated PMN with IL-4 (24 h). (D) Stimulated Ption, it has an effect on B-cells, T-cells, monocytes, mast-
cells, endothelial cells, and ﬁbroblasts [18]. Directly and/or
indirectly, IL-2 has a prominent role in the regulation of IL-
4 producing cells [17]. IL-4 binds to a high-afﬁnity cell-surface
receptor (IL-4R) to exert its effects [19]. It promotes the
growth and differentiation of activated human B-lymphocytes
and shares many biological functions with IL-13 [20].
Following this approach, the present study was undertaken
to estimate the expression of the antigen presenting molecule
MHC class II and the co-stimulatory molecules CD80 and
CD86 on PMN stimulated with IL-2 or IL-4.
2. Materials and methods
2.1. Donors, media, reagents and antibodies
Blood was taken by venous puncture using 7Æ5 ml heparin-
coated tubes (Sarstedt, Nu¨mbrecht, Germany) and analyzed
within 2 h. Recombinant human (rh) IL-2 and IL-4 were pur-
chased from Sigma (St Louis, MO, USA). For ﬂuorescence-
activated cell sorter (FACS) analysis of whole blood, erythro-
cyte FACS lasing solution was obtained from Becton Dichin-
son (Heidelberg, Germany) and diluted 1:10 by bidistilled
water. For cytoﬂuorometry ﬂuorescein isothiocyanate (FITC)
and phycoerythrin (PE)-labeled murine MoAbs were used.ole blood PMN. (A) Unstimulated PMN (0 h). (B) Unstimulated
MN with IL-2 (24 h).
Figure 2 Flow cytometry of the CD80 induction in the whole blood PMN. (A) Unstimulated PMN (0 h). (B) Unstimulated PMN (24 h).
(C) Stimulated PMN with IL-4 (24 h). (D) Stimulated PMN with IL-2 (24 h).
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DP+DQ+DR:PE, CD80:PE and CD86:PE were obtained
from Coulter Immunotech (Marseilles, France).
2.2. Direct ﬂow cytometry analysis
To avoid alteration of antigen expression, PMN from healthy
donors were analyzed in whole blood. For double labeling,
anti-CD66b-FITC as a PMN marker and the respective PE-la-
beled antibody were used in equal protein concentrations. Cells
were analyzed by FACSCalibur and CellQuest software (Bec-
ton Dickinson, SanDiego, CA). Results were expressed as the
percentage of positive cells in the respective gate or quadrant.
2.3. Cultivation and stimulation of PMN
In all sets of experiments PMN in whole blood were cultured in
the presence and absence of IL-2 or IL-4 for 24 h at 37 C with
5% CO2 in air. Heparinized blood was placed into 24-well
plate, 2 ml/well and incubated in the presence or absence of
the activator IL-2 (10 ng/ml) or IL-4 (6 ng/ml) and incubated
for about 24 h at 37 C with 5% CO2.2.4. Statistical analysis
Statistical analysis of the obtained data was performed using
one way analysis of variance (ANOVA) test followed by least
square differences (LSD) analysis (for comparison between
means). Results were expressed as mean ± standard error
(S.E.), and differences were considered to be signiﬁcant at
(P< 0.05).3. Results
Results were expressed as percentages of positive cells in the
respective gate or quadrant. Each set of experiments was re-
peated in vitro several times.
3.1. In vitro expression of MHC class II on PMN
The majority of healthy donors PMN expressed CD66b
(Fig. 1A–D). In the ﬁrst set of experiments the effect of IL-2
on the expression of MHC class II was tested, where the study
found that PMN on whole blood showed expression of MHC
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using IL-2 and IL-4, respectively, as stimulators. In contrast,
fresh and unstimulated cells cultured with medium only count-
ing 1.05% (Fig. 1A) and 2.71% (Fig. 1B), respectively. Statis-
tical analysis showed that, there is a signiﬁcant difference
between IL-4 or IL-2 stimulated cells and unstimulated cells,
also IL-4 stimulated PMN had a signiﬁcant difference from
IL-2 stimulated cells, P< 0.05 (Fig. 4A).
3.2. In vitro induction of CD80 on PMN
As shown for MHC class II, surface expression of CD80 was
most impressive following cultivation of whole blood with
the stimuli for 24 h. The proportion of double-positive cells
(right upper quadrant) was estimated, where CD80 positive
cells was slightly higher in stimulated cells recording 4.06%
by using IL-4 (Fig. 2C) and 7.14% by stimulation with IL-2
(Fig. 2D) than unstimulated cultured with medium for 24 h
(1.12%) and fresh PMN, 0.05% (Fig. 2B and A, respectively).
Fig. 4B showed that, there is a signiﬁcant difference between
IL-4 or IL-2 stimulated cells and unstimulated cells, also IL-Figure 3 FACS for CD86 surface expression in the whole blood PMN
Stimulated PMN with IL-4 (24 h). (D) Stimulated PMN with IL-2 (244 stimulated PMN had a signiﬁcant difference from IL-2 stim-
ulated cells (P< 0.05).
3.3. In vitro induction of CD86 on PMN
For CD86, high expression was recorded on the surface of
both IL-2 stimulated PMN counting 24.20% (Fig. 3D) and
IL-4 stimulated cells recorded 20.48% (Fig. 3C), while percent-
age of CD86 molecules on the surface of unstimulated PMN
cultured with medium alone measured 6.97 (Fig. 3B). Fresh
PMN had 1.55% (Fig. 3A). Statistical analysis also showed
that, there is a signiﬁcant difference between IL-4 or IL-2 stim-
ulated cells and unstimulated cells (P< 0.05). In contrast to
MCH Class II and CD80, there is no signiﬁcant difference be-
tween IL-4 stimulated PMN and IL-2 stimulated cells,
P> 0.05 (Fig. 4C).
4. Discussion
All sets of experiments were carried out in whole blood to
avoid any receptors changes. More than 99% of PMN were. (A) Unstimulated PMN (0 h). (B) Unstimulated PMN (24 h). (C)
h).
Figure 4 Expression of some surface molecules on PMN stimulated with either IL-2 or IL-4. (A) MHC class II expression. (B) CD80
expression. (C) CD86 expression.
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sitive marker of PMN (anti-CD66b-FITC).
PMN are considered short-lived cells undergoing spontane-
ous apoptosis in vivo as well as in culture [21]. Previous studies
have demonstrated that PMN can be induced in vitro to syn-
thesize and release various cytokines, suggesting that these
cells can contribute signiﬁcantly to the initiation and ampliﬁca-
tion of cellular and humoral immune responses [5]. The detec-
tion of these molecules, therefore, provides strong support for
the hypothesis that human PMN can actively synthesize immu-
noregulatory molecules [22] and have the potential to act as
antigen presenting cells [8].
During the last period, it has become increasingly evident
that culturing PMN in the presence of cytokines extends their
life span [23–26]. Cultured PMN synthesize and release immu-
nomodulatory cytokines by which they may participate in the
afferent limb of the immune response [5].
This study has clearly shown that PMN could be induced to
express MHC class II, CD80 and CD86 after activation with
either IL-2 or IL-4. These data are in accordance with other
results where MHC class II, CD80 and CD86 were expressed
on the PMN surface after exposure to GM-CSF and/or
INF-c [6].
The antigen presenting molecule MHC class II and the co-
stimulatory molecules CD80 and CD86 play an important role
in T-cells proliferation, where MHC class II presents the en-gulfed antigen to T-cells [6]. Additionally, CD80 and CD86
act as second signal molecules involving in the stimulation of
T-cells to produce the autocrine growth factor IL-2 without
which T-cells are unable to proliferate [27].
The activation and recruitment of PMN were also regulated
by IL-15 [13], IFN-c [28], CSF-CSF [29–31] and IL-8 [32]. In
addition, PMN possess IL-2Rb chain [16,33] and IL-2Rc chain
[34] that have the ability to bind with IL-4 [35]. These pub-
lished data prompted us to study the effect of IL-2 and IL-4
on PMN functions.
In conclusion, stimulated PMN with either IL-2 or IL-4
lead to expression of the antigen presenting molecules (MHC
class II) and the co-stimulatory molecules (CD80 and
CD86). These molecules play an important role in antigen pre-
sentation and consequently T-cell proliferation [36]. This
means that IL-2 and also IL-4 stimulated PMN might be in-
volved indirectly in acquired immune response in addition to
their role in innate immunity.Acknowledgements
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